Biote's business model is anchored in a differentiated, technology-enabled hormone optimization service integrated with proprietary software and vertically integrated manufacturing. The annuity-based revenue model backed by a large practitioner network supports recurring revenue, though recent soft…
Biote Corp. (BTMD) Q4 2024: 9% Revenue Growth Amid Software Transition Challenges
Biote achieved solid top-line growth driven by established clinics despite transitional headwinds from upgraded clinical software. Margin expansion reflects successful vertical integration and cost management. Leadership outlines clear focus on practitioner network expansion and commercial execution to accelerate growth in 2025.
Summary
- Competitive Differentiation Strengthened: Proprietary clinical software and BioTRx platform enhance practitioner capabilities and patient care.
- Operational Focus Shift: Temporary slowdown in new practitioner onboarding due to software rollout and training emphasis.
- Growth Reacceleration in Sight: Management prioritizes practitioner recruitment and commercial discipline to drive procedure revenue expansion.
Business Overview
Biote Corp. operates as a personalized hormone optimization and therapeutic wellness provider, generating revenue primarily through procedure services and product sales. Its major segments include procedure revenue from hormone pellet treatments at certified clinics and dietary supplement sales, with growing emphasis on proprietary platforms such as BioTRx and clinical decision support software that support practitioners in delivering individualized care.
Performance Analysis
In the fourth quarter of 2024, Biote reported $49.8 million in revenue, marking a 9% increase year-over-year, driven mainly by a 5% rise in procedure revenue from established top-tier clinics. Dietary supplement revenue grew 10.2%, benefiting from the ongoing transition of part of this business to the Amazon e-commerce channel, which remains in its final stages. Gross profit margin improved to 71.8%, a 247 basis point increase compared to the prior year, reflecting cost efficiencies from vertical integration of the 503B manufacturing facility and disciplined cost management.
Despite revenue growth, net income declined to $3.5 million from $12.1 million in the prior-year quarter, primarily due to increased employee-related investments and legal expenses, as well as an $800,000 loss from changes in earnout liabilities. Adjusted EBITDA rose 11.4% to $15.1 million, with margin expansion to 30.3%, underscoring operational leverage in the business model. Cash flow from operations strengthened significantly to $45.2 million for the full year, up from $26.9 million in 2023, reinforcing Biote’s strong cash-generating capacity.
- Revenue Growth Drivers: Established clinic growth offset transitional softness from clinical software upgrades.
- Margin Expansion Catalyst: Vertical integration and cost control improved gross profit despite higher SG&A spend.
- Profitability Dynamics: Net income pressured by investments and legal costs, while Adjusted EBITDA margin improved.
Overall, Biote’s financial results reflect a resilient core business navigating short-term operational challenges while positioning for longer-term growth through strategic investments and enhanced practitioner tools.
Executive Commentary
"Over the past year, Biote has laid the groundwork to achieve accelerated growth by strengthening our competitive moat through proprietary offerings and vertical integration. Our upgraded clinical decision support software and BioTRx platform uniquely position us to deliver individualized therapies and expand our market reach."
Brett Christensen, Chief Executive Officer
"Fourth quarter revenue increased 9% despite headwinds from the software transition and practitioner training focus. Our gross profit margin expanded by nearly 250 basis points due to vertical integration and cost management, and we generated over $45 million in operating cash flow for the year."
Bob Peterson, Chief Financial Officer
Strategic Positioning
1. Proprietary Clinical Decision Support Software as a Growth Lever
Biote’s upgraded clinical decision support software, launched in Q3 2024, incorporates evidence-based, proprietary dosing algorithms that enhance practitioner ability to deliver personalized hormone optimization and wellness therapies. Despite initial transitional disruptions impacting procedure volume and new clinic onboarding, management views this software as a key competitive moat that broadens appeal to a wider practitioner base and expands treatment options.
2. Vertical Integration via Asteria Health Acquisition
The 2024 acquisition of Asteria Health enabled Biote to internalize manufacturing of hormone pellets and compounded products under the 503B facility, improving supply chain control and cost efficiency. This vertical integration drove a notable improvement in gross profit margin and provides capacity to scale pellet production prudently while maintaining practitioner satisfaction.
3. Expansion of Practitioner Network and Training
Biote’s practitioner network exceeds 8,600 providers, including approximately 4,700 clinics. The company is intensifying efforts to onboard new practitioners rapidly through its Quick Start training program, which requires significant physician commitment. Management acknowledges the slowdown in new practitioner additions during the software rollout but is focused on rebuilding growth momentum to drive procedure revenue.
4. BioTRx Platform as a Comprehensive Wellness Offering
BioTRx, Biote’s wellness platform, integrates product ordering, inventory management, and clinical support, serving as a platform for current and future product expansion. While GLP-1 compounds like semaglutide are included as ancillary offerings, hormone optimization remains the core business. The platform supports potential future additions, enhancing long-term growth opportunities.
5. Commercial Execution and Organizational Discipline
New CEO Brett Christensen emphasizes strengthening commercial accountability, consistency, and discipline to improve sales force effectiveness. The goal is to accelerate new clinic starts and practitioner engagement, which are critical growth drivers in Biote’s annuity-based model. These efforts are expected to yield results later in 2025 as execution improves.
Key Considerations
Biote’s fourth quarter results and management commentary highlight several strategic and operational factors shaping the company’s trajectory:
- Software Transition Impact: The upgraded clinical decision support software, while strategically important, temporarily slowed procedure volume growth and new clinic onboarding due to practitioner training demands.
- Annuitized Revenue Model: Growth depends heavily on consistent new practitioner additions to offset attrition in the annuity revenue stream, underscoring the importance of commercial execution.
- Vertical Integration Benefits: Internal manufacturing via Asteria Health enhances margin structure and supply reliability, representing a durable competitive advantage.
- Platform Expansion Potential: BioTRx serves as a scalable platform for wellness products beyond hormone pellets, though current revenue contribution from GLP-1s remains ancillary.
- Investment in Growth: Increased SG&A reflects deliberate investments in personnel and legal matters, which weigh on near-term profitability but aim to support sustainable expansion.
Risks
Biote faces risks from the operational disruption associated with software transitions, which could extend new practitioner onboarding delays and impact procedure revenue growth. Competitive pressures and regulatory oversight in hormone optimization and wellness markets remain significant. Additionally, reliance on practitioner adoption and patient acceptance introduces execution risk, while legal expenses and integration challenges from acquisitions could affect financial performance.
Forward Outlook
For fiscal year 2025, Biote projects revenue between $202 million and $208 million, reflecting 2% to 4% growth in procedure revenue and 5% to 10% growth in dietary supplement sales. First quarter revenue is expected to be slightly higher year-over-year due to ramped training and onboarding, while adjusted EBITDA is forecasted to decline approximately 5% compared to Q1 2024, reflecting increased sales and marketing investments to accelerate new customer growth.
Takeaways
Biote’s Q4 2024 results illustrate a company in transition, balancing short-term operational challenges with long-term strategic investments:
- Growth Moderation Reflects Transition: Software upgrades and practitioner training temporarily slowed new clinic starts, impacting procedure revenue growth despite solid performance from existing clinics.
- Margin Expansion Validates Vertical Integration: Internal manufacturing efficiencies and cost discipline improved gross profit margins, underscoring the value of supply chain control.
- Execution Focus Critical for Future Growth: Management’s emphasis on commercial discipline and practitioner network expansion will be key to reaccelerating revenue growth and realizing the full potential of proprietary platforms.
Conclusion
Biote demonstrated resilience with 9% revenue growth and margin expansion in Q4 2024 despite transitional headwinds from software implementation and practitioner onboarding delays. The company’s strategic investments in proprietary technology, vertical integration, and commercial execution position it well for growth acceleration in 2025, contingent on successful practitioner network expansion and operational execution.
Industry Read-Through
Biote’s experience highlights the operational complexities of integrating advanced clinical decision support software in personalized healthcare delivery models. The vertical integration of manufacturing in hormone optimization underscores a broader industry trend toward supply chain control to improve margins and product quality. Additionally, the cautious approach to incorporating GLP-1 compounds reflects the evolving competitive landscape in therapeutic wellness, where companies must balance core offerings with emerging adjunct therapies. Other players in personalized medicine and wellness sectors should monitor Biote’s execution of practitioner onboarding and platform expansion as indicators of sustainable growth strategies amid technological and regulatory challenges.